A study of lanabecestat (LY3314814) in healthy participants

Exclusion Criteria

• - Have a history of or current, significant ophthalmic disease, as determined by the investigator or ophthalmologist
• - Have vitiligo or any other clinically significant disorder of skin pigmentation as determined by the investigator or dermatologist
• - History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• - History of previous or ongoing psychiatric disease/condition
• - Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study, or have a history of significant dysrhythmias or atrioventricular (AV) block (including first degree AV block). Participants with history of persistent PR interval greater than (>)200 milliseconds (msec) will be excluded
• - Have prolonged Fridericia-corrected QT interval (QTcF) of >470 msec
• - Have a clinically significant abnormal blood pressure or heart rate (supine) as
• determined by the investigator
• - Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
• - Are unwilling to comply with the dietary requirements/restrictions during the study
• - Evidence of active renal disease (e.g, diabetic renal disease, polycystic kidney disease) or calculated creatinine clearance <50 milliliters per minute (mL/min)